azacitidine has been researched along with arsenic trioxide in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| List, AF | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Fukumoto, JS; Greenberg, PL | 1 |
| Pu, Q | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Chang, H; Chen, G; Feng, Y; Huang, H; Lin, F; Sun, A; Wang, Y; Wu, D | 1 |
| Bartlett, DL; Gorry, MC; Guo, ZS; Li, Q; O'Malley, ME | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Jiang, J; Liu, XS; Peng, CY; Zheng, HT | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Guo, LP; Li, LW; Li, XY; Lu, SX; Yu, XY; Zhou, Y | 1 |
| Luo, JM; Sun, J; Zhang, XK | 1 |
| Chan, TS; Chau, D; Cheng, YY; Fong, B; Kwong, YL; Ng, K; Tam, S; Tse, E | 1 |
| Feng, L; Li, XY; Li, Y; Liu, X; Wang, X; Zhang, L | 1 |
| Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J | 1 |
| Chiu, JF; Huang, N; Li, G; Lin, W; Pei, X; Tao, T | 1 |
| Naoe, T | 1 |
| Herold, T; Hiddemann, W; Rausch, C; Spiekermann, K; von Bergwelt-Baildon, M | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
6 review(s) available for azacitidine and arsenic trioxide
| Article | Year |
|---|---|
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
Management of patients with higher risk myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Azacitidine; Combined Modality Therapy; Disease-Free Survival; Farnesyltranstransferase; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Oxides; Prognosis; Risk Factors; Treatment Outcome | 2005 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for azacitidine and arsenic trioxide
| Article | Year |
|---|---|
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
15 other study(ies) available for azacitidine and arsenic trioxide
| Article | Year |
|---|---|
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
[Further improving the standard of treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2006 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Oxides; RNA, Messenger; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, Homeobox; Growth Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Male; Mice; Oxides; Pyridines; Transcription Factors; Up-Regulation | 2009 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid | 2010 |
[Mechanism of loss of human esophageal cancer-related gene 4 (ECRG4) gene expression in esophageal squamous cell carcinoma cell line EC9706].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Esophageal Neoplasms; Exons; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Oxides; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2011 |
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; K562 Cells; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; TYK2 Kinase | 2014 |
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aquaporins; Arsenic Trioxide; Arsenicals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Oxides; Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation | 2015 |
The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Tumor; Cell Survival; DNA (Cytosine-5-)-Methyltransferase 1; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oxides; Wnt Signaling Pathway | 2017 |
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2017 |
DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Lung; NAD(P)H Dehydrogenase (Quinone); Oxides; Promoter Regions, Genetic; Rats | 2018 |
[Acute Myeloid Leukemia - Update 2022].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin | 2022 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |